



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 19<sup>TH</sup> AUGUST 2020

#### PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr R Ahmed (RA)	GP BwD CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Dr J Adiyodi (JA)	Consultant Haematologist, ELHT (part of meeting)
Mrs C Harding (CH)	Pharmacist, Lancashire Care Foundation Trust (part of meeting)

#### 2020/069: APOLOGIES:

Dr Duncan Gavan	Consultant Radiologist, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr T McKenzie (TM)	GP East Lancs
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

#### 2020/070: DECLARATION OF INTEREST

None declared – relevant to agenda items.

#### 2020/071: MINUTES OF JULY Teams MEETING:

Accepted as a correct record.

#### 2020/072: MATTERS ARISING:

**2019/131: Treatment of Vitamin B12 Deficiency Draft** – A pathway is currently being developed with Jane Oakey from Path Lab who is exploring options re. active B12 testing in the lab. LR to obtain update on progress. To be brought to ELMMB when completed.

**2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta®** - JV arranging meeting to consider their place on primary care guidelines

**2020/020: Formulary Updates - Ranolazine & Ivabradine** – Dr Singh to assist with producing a Hot Topic to support GP prescribing. JV to follow up.

**2020/031: NICE Recommendations (from Feb) – Patiromer** – Red Traffic light confirmed as RED.

## **2020/073: NEW PRODUCT REQUEST – ISAVUCONAZOLE**

Presented by Dr Nural Amir, Consultant Microbiologist.

Isavuconazole is a triazole antifungal similar to voriconazole, available for oral and IV use licensed for invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate. It is as effective as voriconazole and dose adjustments are not required for the elderly, renal or hepatic impairment. It is recommended in ECIL-6, ESCMID, ECMM & IDSA guidelines as a first line alternative to voriconazole.

Isavuconazole is very expensive (over 200 times more than voriconazole). The request is to use only if there have been side effects to voriconazole (ie second line) and on consultant microbiologist advice. ELMMB agreed to add to formulary on consultant microbiologist advice only. Clear guidance on its use is to be written and agreed by antimicrobial stewardship committee and included in the Antimicrobial Microguide.

**Resolved: Isavuconazole to be included in formulary on advice of consultant microbiologist only. Clear guidance on its use to be included in Antimicrobial Microguide.**

**Traffic Light: RED**

## **2020/074: LSCMMG CONSULTATIONS (FOR SEPTEMBER LSCMMG)**

**Primary Care Psoriasis Guidelines** – While it is recognised that this guideline follows NICE guidance there is concern that there are too many steps each taking many weeks. The Primary Care Dermatology Society pathway recommends combination products first line once a day rather than starting with separate agents.

Summary of feedback for LSCMMG: the guidance is not considered practical for GPs and patients with the long timescales involved, modifiable risk factors are not included, descaling early on is not included, and should calcipotriol + betamethasone foam be included.

**Mentorix Vaccine for Respiratory Conditions New Medicines Assessment** – The recommendation does not address the indication that the respiratory consultants are recommending it for. They request its administration as a test of the immune system with functional antibody testing as referenced in BTS guidelines. There are no commissioning arrangements for this vaccine.

**Resolved: Comments to be sent to LSCMMG.**

## **2020/075: LSCMMG Recommendations**

**Guidelines for prescribing nutritional supplements post bariatric surgery** – accepted as written for ELHE.

**Assessing suitability for strong opioid use** – this guideline is intended as supplementary guidance alongside other pain guidelines. NICE have just issued a consultation on draft guidance for chronic pain which does not include opioids. Guideline not adopted in ELHE. Await publication of NICE guidance on chronic pain.

## **2020/076: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS**

No meeting.

## **2020/077: FORMULARY UPDATES**

**Nizatidine** – option for therapy during supply issues with all H2 antagonists. Agreed to add to formulary where PPIs are not tolerated or not appropriate. Lansoprazole / omeprazole remain as first line alternatives.

**Tacrolimus prolonged release - Advagraf®** - many patients started on this brand by renal centres following transplant. Add to formulary. **Traffic Light: RED**

**TB Fixed Dose Combinations for children** – WHO recommend using child-friendly fixed dose combinations for the treatment of TB in children. Add to formulary RHZ 75/50/150 for intensive phase and RH 75/50 for continuation phase. **Traffic Light: RED**

**Sumatriptan 3mg pre-filled pen** – requested by neurologists. Place in therapy not clear.

**Action:** To request further information from neurologists on the cohort of patients it may be required for. VG to follow up with neurology pharmacist at LTH.

**Methylphenidate prolonged release - Delmosart®** - community paediatrics and ELCAS would like to use this cost effective alternative brand for new patients. It is already included in the shared care guidance. Add to formulary for use in paediatrics.

**Traffic Light: AMBER**

**Carbomer Single Use Eye Drops (Viscotears®)** – for use on NICU during eye screening. Add to formulary for NICU only. **Traffic Light: RED**

**Sodium chloride 0.9% for nebulisation** – it is included in palliative care guidance for breathlessness. Concerns have been raised previously over costs due to variety of unlicensed preparations procured in the community. Some licensed preparations are listed in BNF.

**Action:** LR/JV to explore if a branded product could be included to ensure cost effective products used.

**CUES eye products** – COVID-19 Urgent Eye Care Service led by community Optometrists are recommending patients purchase some appropriate OTC items and also have a list of prescription only eye products they would like to prescribe. This list includes some non-formulary products.

**Action:** LR/JV to suggest alternative formulary products and advise to complete a New Drugs Request form for any non-formulary products they would like available, and if required invite to next ELMMB meeting.

**GlucoRx safety needles** – changed to this brand of needles some time ago. There have been a number of complaints from nurses with respect to them being faulty. The company has received concerns elsewhere as it appears the needles were being used incorrectly and as a result the company offers a training programme.

**Action:** VG to send information and materials re training out via Medicines Safety Group

**Resolved: Formulary to be updated as above**

## **2020/078: ELHT: ANTIMICROBIAL FORMULARY**

Impetigo guidelines – updated in line with recent NICE guidance

Leg ulcer infection (non-diabetic patients) – new guideline in line with NICE

Amphotericin B monograph – new guidance

Line infections antimicrobial therapy – new guidance

Diabetic foot ulcer guidelines – updated in line with recent NICE guidance

**Resolved: New and updated guidance acknowledged.**

## **2020/079: NICE RECOMMENDATIONS (from July)**

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [TA638] is recommended as an option by NICE. Approved in line with NICE.  
NHS England Commissioned **Traffic Light: RED**

Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639) is recommended as an option by NICE. Approved in line with NICE.  
NHS England Commissioned **Traffic Light: RED**

## **2020/080: EAMS: LUMASIRAN**

Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in adults and children of all ages.

**Resolved: EAMS Lumasiran acknowledged**

## **2020/081: FREE OF CHARGE SCHEME NHSE APPROVED**

Darolutamide for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

**Resolved: FOC for Darolutamide acknowledged**

**STANDING ITEMS**

**2020/082: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA  
MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – July 2020**

Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 16<sup>th</sup> September 2020 12.30pm via  
'Microsoft Teams'**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 19<sup>th</sup> AUGUST 2020**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/131</b>	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed. Check on progress	LR/JV LR	Feb 20 Sept 20
<b>2020/015</b>	<b>New Product request – Relvar Ellipta® &amp; Anoro Ellipta®</b> - meeting to be arranged to consider place on primary care guidelines	JV	Sept 20
<b>2020/020</b>	<b>Formulary Updates – Ranolazine &amp; Ivabradine</b> – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh Follow up with Dr Singh	JV JV	Apr 20 Aug 20
<b>2020/077</b>	<b>Formulary Updates</b> <ul style="list-style-type: none"> <li>- <b>Sumatriptan 3mg pre-filled pen</b> Request further information from neurologists - Check with neurology pharmacist at Preston</li> <li>- <b>Sodium chloride 0.9% for nebulisation</b> Explore if a branded product could be included to ensure cost effective products used.</li> <li>- <b>CUES eye products</b> Suggest alternative formulary products, advise them to complete a request for any non-formulary products they still would like available, and if required invite them to next ELMMB meeting.</li> <li>- <b>Glucorx safety needles</b> Send information and materials re training out via Medicines Safety Group</li> </ul>	VG LR/JV LR/JV VG	Sep 20 Sep 20 Sep 20 Sep 20